[Comment] Immune checkpoint inhibitors: the next step for thymic carcinomas

Thymic carcinoma is a rare cancer with few available treatment options. Over the past few years, chemotherapy for thymic malignancies, comprising thymic carcinomas and thymomas, has achieved minimal success. Therefore, a more promising, targeted approach is required.1

Source: The Lancet Oncology - January 25, 2018 Category: Cancer & Oncology Authors: Yusuke Okuma Tags: Comment Source Type: research